Organization Description
Senolytic Therapeutics (STX) is developing proprietary strategies to destroy the senescent cells that generate the senescence-associated secretory phenotype (SASP) and harm tissues, thus treating one of the hallmarks of aging and associated age-related diseases.
It has a treatment program focused on removing fibrotic tissue and treating specific kinds of cancer, is working on an immune system-based treatment for cancer cells that have been made senescent through other therapies, and is attempting to discover other compounds that have senolytic effects. The company has offices in Barcelona, Spain, and Boston, Massachusetts and is co-founded by Dr. Manuel Serrano and Dr. Marc Ramis Castelltort. It is a daughter company of Life Biosciences, which owns multiple rejuvenation biotechnology companies each focusing on a different hallmark of aging.
